Efficacy and safety of mycophenolate mofetil versus cyclophosphamide in the treatment of Henoch-Schönlein purpura nephritis with nephrotic-range proteinuria in children: a prospective randomized controlled trial.
- Author:
Hai-Yun GENG
1
;
Chao-Ying CHEN
1
;
Hua-Rong LI
1
;
Juan TU
1
;
Pei-Wei DU
1
;
Hua XIA
1
Author Information
1. Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Child;
Cyclophosphamide/adverse effects*;
Humans;
Immunosuppressive Agents/adverse effects*;
Mycophenolic Acid/adverse effects*;
Nephritis/drug therapy*;
Prospective Studies;
Proteinuria/etiology*;
Purpura, Schoenlein-Henoch/drug therapy*;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(4):338-342
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the efficacy and safety of mycophenolate mofetil (MMF) versus cyclophosphamide (CTX) in the treatment of children with Henoch-Schönlein purpura nephritis (HSPN) and nephrotic-range proteinuria.
METHODS:A prospective clinical trial was conducted in 68 pediatric patients who were admitted to the Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics and who were diagnosed with HSPN and nephrotic-range proteinuria from August 2016 to November 2019. The patients were randomly divided into two groups:MMF treatment (
RESULTS:At months 3, 6, and 12 of treatment, there was no significant difference in the complete remission rate and the response rate between the MMF treament and CTX treatment groups (
CONCLUSIONS:MMF and CTX have similar efficacy and safety in the treatment of HSPN children with nephrotic-range proteinuria.
